-
Je něco špatně v tomto záznamu ?
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
MA. Dimopoulos, P. Moreau, B. Augustson, N. Castro, T. Pika, S. Delimpasi, J. De la Rubia, A. Maiolino, T. Reiman, J. Martinez-Lopez, T. Martin, J. Mikhael, K. Yong, ML. Risse, G. Asset, S. Marion, R. Hajek
Jazyk angličtina Země Spojené státy americké
Typ dokumentu dopisy
NLK
Free Medical Journals
od 1998 do Před 1 rokem
Wiley Free Content
od 1996 do Před 1 rokem
PubMed
35604280
DOI
10.1002/ajh.26602
Knihovny.cz E-zdroje
- MeSH
- dexamethason terapeutické užití MeSH
- humanizované monoklonální protilátky terapeutické užití MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie MeSH
- mnohočetný myelom * farmakoterapie MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
Departamento de Hematología Hospital 12 de Octubre Complutense University Madrid Spain
Department of Haematology General Hospital of Athens Athens Greece
Department of Haematology University College Hospital London UK
Department of Hemato Oncology Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Hemato Oncology University Hospital Olomouc Olomouc Czech Republic
Department of Hemato Oncology University Hospital Ostrava Ostrava Czech Republic
Department of Hematology University Hospital Hôtel Dieu Nantes France
Hematology Department University Hospital La Fe Valencia Spain
Hospital de Cancer de Barretos São Paulo Brazil
Sanofi Cambridge Massachusetts USA
Sir Charles Gairdner Hospital Perth Western Australia Australia
The National and Kapodistrian University of Athens Athens Greece
Translational Genomics Research Institute City of Hope Cancer Center Phoenix Arizona USA
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032090
- 003
- CZ-PrNML
- 005
- 20230131150652.0
- 007
- ta
- 008
- 230120s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.26602 $2 doi
- 035 __
- $a (PubMed)35604280
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Dimopoulos, Meletios A $u The National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000189903254
- 245 10
- $a Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis / $c MA. Dimopoulos, P. Moreau, B. Augustson, N. Castro, T. Pika, S. Delimpasi, J. De la Rubia, A. Maiolino, T. Reiman, J. Martinez-Lopez, T. Martin, J. Mikhael, K. Yong, ML. Risse, G. Asset, S. Marion, R. Hajek
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $x farmakoterapie $7 D009101
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a dexamethason $x terapeutické užití $7 D003907
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $7 D009364
- 655 _2
- $a dopisy $7 D016422
- 700 1_
- $a Moreau, Philippe $u Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France $1 https://orcid.org/0000000317808746
- 700 1_
- $a Augustson, Bradley $u Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
- 700 1_
- $a Castro, Nelson $u Hospital de Cancer de Barretos, São Paulo, Brazil
- 700 1_
- $a Pika, Tomas $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Delimpasi, Sosana $u Department of Haematology, General Hospital of Athens, Athens, Greece $1 https://orcid.org/0000000175237510
- 700 1_
- $a De la Rubia, Javier $u Hematology Department, University Hospital La Fe, Valencia, Spain
- 700 1_
- $a Maiolino, Angelo $u Instituto COI de Ensino e Pesquisa and Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
- 700 1_
- $a Reiman, Tony $u Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, New Brunswick, Canada
- 700 1_
- $a Martinez-Lopez, Joaquin $u Departamento de Hematología, Hospital 12 de Octubre, Complutense University, Madrid, Spain
- 700 1_
- $a Martin, Thomas $u UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
- 700 1_
- $a Mikhael, Joseph $u Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA $1 https://orcid.org/0000000196702864
- 700 1_
- $a Yong, Kwee $u Department of Haematology, University College Hospital, London, UK
- 700 1_
- $a Risse, Marie-Laure $u Sanofi, Vitry-sur-Seine, France
- 700 1_
- $a Asset, Gaelle $u Sanofi, Chilly-Mazarin, France
- 700 1_
- $a Marion, Sylvia $u Sanofi, Cambridge, Massachusetts, USA
- 700 1_
- $a Hajek, Roman $u Department of Hemato-Oncology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Hemato-Oncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 98, č. 1 (2023), s. E15-E19
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35604280 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131150648 $b ABA008
- 999 __
- $a ok $b bmc $g 1891085 $s 1183425
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 98 $c 1 $d E15-E19 $e 20220604 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- LZP __
- $a Pubmed-20230120